Pancreatic Cancer Research

ResearcherMorgan State UniversityActive in the last 2 years

Ashraf Mohamadkhani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0744-0634; OpenAlex author ID A5042396173. Sources: OpenAlex.

Their work

Papers
16 (first author 4, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 16

  1. Causal Exposures in Pancreatic Cancer Incidence: Insights From Mendelian Randomization Studies. Co-author DOI 10.1002/jgh3.70105↗
  2. The association of dietary intake and plasma fatty acid panel in pancreatic cancer patients: Results from Golestan cohort study. Co-author DOI 10.1177/02601060221114712↗
  3. Protective Effect of Dehydroepiandrosterone (DHEA) On Pancreatic Cancer Through C-Reactive Protein (CRP) Production Inhibition. First author DOI 10.61186/rbmb.13.2.174↗
  4. RNA-sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients. Co-author DOI 10.1002/cbin.11924↗
  5. Dehydroepiandrosterone modulates oxidative DNA damage in pancreatic cancer: A case-control study. First author DOI 10.1002/jgh3.12604↗
  6. Circulating plasma fatty acids and risk of pancreatic cancer: Results from the Golestan Cohort Study. First author DOI 10.1016/j.clnu.2020.09.002↗
  7. Dietary intake of fatty acids and risk of pancreatic cancer: Golestan cohort study. Co-author DOI 10.1186/s12937-021-00723-3↗
  8. Diagnostic Significance of Serum Fatty Acid Synthase in Patients with Pancreatic Cancer. Last author DOI 10.34172/mejdd.2021.214↗
  9. Oral microbial community composition is associated with pancreatic cancer: A case-control study in Iran. Co-author DOI 10.1002/cam4.2660↗
  10. An Increased Level of Aryl Hydrocarbon Receptor in Patients with Pancreatic Cancer. Last author DOI 10.15171/mejdd.2018.126↗
  11. Mutations in Known and Novel cancer Susceptibility Genes in Young Patients with Pancreatic Cancer. First author PMID 29940740↗
  12. Pancreatic Cancer is Associated with Peripheral Leukocyte Oxidative DNA Damage Co-author DOI 10.22034/apjcp.2017.18.5.1349↗
  13. Opium use, cigarette smoking, and alcohol consumption in relation to pancreatic cancer. Co-author DOI 10.1097/md.0000000000003922↗
  14. Direct Sequencing of Cyclooxygenase-2 (COX-2) Revealed an Intronic Variant rs201231411 in Iranian Patients with Pancreatic Cancer. Co-author PMID 25628848↗
  15. Network of microRNAs-mRNAs interactions in pancreatic cancer. Last author DOI 10.1155/2014/534821↗
  16. Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. Co-author DOI 10.1155/2013/738915↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akram Pourshams · 16 shared papers, 2013–2025 · strength 2.19
  2. Sahar Masoudi · 6 shared papers, 2018–2024 · strength 0.86
  3. Hamid Reza Fazli · 5 shared papers, 2013–2024 · strength 0.75
  4. Azita Hekmatdoost · 3 shared papers, 2021–2024 · strength 0.51
  5. Neda Ghamarzad Shishavan · 3 shared papers, 2021–2024 · strength 0.51
  6. Ramin Shakeri · 2 shared papers, 2016–2025 · strength 0.38
  7. Mojtaba Jafarinia · 1 shared paper, 2024 · strength 0.28
  8. Paolo Boffetta · 3 shared papers, 2016–2018 · strength 0.20
  9. Zahra Madjd · 1 shared paper, 2023 · strength 0.19
  10. Alberto D’Angelo · 1 shared paper, 2023 · strength 0.19
  11. Sima Kalantari · 1 shared paper, 2023 · strength 0.19
  12. Mojtaba Jafari Niya · 1 shared paper, 2021 · strength 0.17
  13. Elnaz Naderi · 3 shared papers, 2013–2015 · strength 0.16
  14. Reza Malekzadeh · 2 shared papers, 2016–2017 · strength 0.11
  15. Emily Vogtmann · 1 shared paper, 2020 · strength 0.09
  16. Sarah Mirzaie · 1 shared paper, 2018 · strength 0.09
  17. Marco E. M. Peluso · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.